Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.
about
3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cellsPhase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (Palladia(®)) in Dogs with Spontaneous Malignancies.The role of chemokines in Guillain-Barré syndrome.Chemokines as Cancer Vaccine Adjuvants.MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitroThe effect of lung cancer on cytokine expression in peripheral blood mononuclear cellsAntibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.How do cytokines trigger genomic instability?Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor modelsAltered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivoProduction of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapyMorphoproteomic-Guided Host-Directed Therapy for Tuberculosis.Reprogrammed chondrocytes engineered to produce IL-12 provide novel ex vivo immune-gene therapy for cancer.Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.Targeting Myeloid-Derived Suppressor Cells in Cancer.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.
P2860
Q30850591-0281CE60-C78F-452C-B4BE-8D4C4BB5F9FEQ33428144-A0BAA85C-4398-4E58-B5CC-03DF0F7C74C9Q33624382-FFEC6B71-1B0D-454C-92E9-D4166DE88553Q33792344-7D2D675A-F1AD-495D-8F4A-F7045FF14C63Q34615021-D885D7AC-3C6F-4938-9BD2-6428EF7D4489Q34769405-5B2ACDA3-6669-4E85-A272-6F5E2B7331A3Q35163167-DF0840B7-A79D-4510-867A-7B2CF7841A7DQ36057809-D89674AA-A59F-4B7E-94D9-A8DB38D90FE8Q36827406-D046B3EA-C5DD-40E2-9355-8E943329193FQ36962599-625EDFB1-71B5-4175-8A9A-CB25D3A5AD8DQ37269115-0A06ED10-BB53-492C-A6AC-3F633127E308Q37543402-1191EAE0-5C3C-42DD-8935-1D80DF37B57CQ37619959-B8721A95-B9D2-409D-B2FF-2DAC136863FDQ38715214-CCCFDB7F-FD5D-4B84-8D9F-1B3FE91496C3Q39146408-F1CCFE29-9061-4D94-ACBB-52DE35B06F4BQ39185087-8A88F8AA-7C22-4913-A37D-0726DAFE87BFQ47719808-70825B20-2B22-40DD-B73A-572F86B9A6E1Q47765346-ACEE874B-8043-4BB7-A889-ADD9048E72ECQ51786117-BFD5E246-D431-4B53-BCC5-4D8F3DAE6BBF
P2860
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Chemokines, costimulatory mole ...... immunotherapy of solid tumors.
@ast
Chemokines, costimulatory mole ...... immunotherapy of solid tumors.
@en
type
label
Chemokines, costimulatory mole ...... immunotherapy of solid tumors.
@ast
Chemokines, costimulatory mole ...... immunotherapy of solid tumors.
@en
prefLabel
Chemokines, costimulatory mole ...... immunotherapy of solid tumors.
@ast
Chemokines, costimulatory mole ...... immunotherapy of solid tumors.
@en
P2093
P2860
P356
P1433
P1476
Chemokines, costimulatory mole ...... immunotherapy of solid tumors.
@en
P2093
Alan L Epstein
Melissa G Lechner
Rikki S Bass
Sarah M Russell
P2860
P304
P356
10.2217/IMT.11.115
P577
2011-11-01T00:00:00Z